Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria
The DOI matches its Crossref record.
Abstract
A two-centre, double-blind, randomized, placebo (P)-controlled, parallel-group study was conducted in the UK to examine the efficacy and safety of mizolastine (M), a new H1-receptor antagonist, as a once-daily 10-mg dose in chronic idiopathic urticaria. Fifty-six outpatients (M: n = 28; P: n = 28) with a mean age of 38 +/- 15 years, a duration of disease of more than 3 years, and symptoms of urticaria at least twice a week in the absence of treatment were recruited. After a single-blind placebo run-in period, patients were allocated to one of two treatment groups and were evaluated after 7 and 28 days. The main characteristics (age, duration of disease, number of urticarial episodes, and total score) of the two groups were comparable at inclusion. Mizolastine was shown to improve the urticaria symptoms: at the end of the study, mizolastine produced a significantly greater decrease in the global symptom score comprising itch, wheals, and erythema (M: 2.1 +/- 2.1 vs P: 0.4 +/- 2.0; P = 0.002). The patient-rated global discomfort from symptoms measured by visual analog scale was significantly improved with mizolastine (M: 31.4 +/- 36.7) compared to placebo (P: 5.4 +/- 27.6; P = 0.003), with respectively more M responders (74.1%) than P responders (28.6%, P = 0.001), a responder being a patient with a > or = 50% decrease in VAS. Premature dropouts due to lack of efficacy and loss to follow-up mainly occurred at the first evaluation (day 7) and were more often observed in patients in the placebo group (n = 17) than in the mizolastine group (n = 8) (P = 0.031). No serious adverse events were recorded. Somnolence was reported in two mizolastine patients, one of whom discontinued the study. Thus, mizolastine may be considered a new treatment option for the symptoms of chronic urticaria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Maurer, M., Weller, K., Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P. J., Bousquet, J., Canonica, G. W., Church, M. K., Godse, K. V., Grattan, C. E. H., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02496.x · Cited by 843
EAACI/GA²LEN/EDF/WAO guideline: management of urticaria
Zuberbier, T., Asero, R., Bindslev‐Jensen, C., Walter Canonica, G., Church, M. K., Giménez‐Arnau, A. M., Grattan, C. E. H., Kapp, A., Maurer, M., Merk, H. F., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02178.x · Cited by 527
EAACI/GA2LEN/EDF guideline: management of urticaria
Zuberbier, T., Bindslev‐Jensen, C., Canonica, W., Grattan, C. E. H., Greaves, M. W., Henz, B. M., Kapp, A., Kozel, M. M. A., Maurer, M., Merk, H. F., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2005.00962.x · Cited by 461
Van Zele, T., Gevaert, P., Watelet, J.-B., Claeys, G., Holtappels, G., Claeys, C., van Cauwenberge, P., & Bachert, C. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.07.013 · Cited by 452
Greaves, M. W. (2005) · Skin Pharmacology and Physiology · doi:10.1159/000086667 · Cited by 63
Metadata
- Authors
- Brostoff, J., Fitzharris, P., Dunmore, C., Theron, M., & Blondin, P.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 1996-05
- Volume
- 51
- Issue
- 5
- Pages
- 320-325
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2070167969
- Cited by
- 65
- References
- 0
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. https://app.cochat.ai/papers/10.1111/j.1398-9995.1996.tb00092.x
- The paper
- Brostoff, J., Fitzharris, P., Dunmore, C., Theron, M., & Blondin, P. (1996). Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy. https://doi.org/10.1111/j.1398-9995.1996.tb00092.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.